Breaking News: Higher Dose of Wegovy Ups Weight Loss but Also Side Effects
A recent trial has revealed that a higher weekly dose of the weight loss medication Wegovy leads to greater weight loss than the standard amount, but also increases the risk of side effects. The study found that patients who received the higher dose lost an average of 18% of their body weight over a year, compared to 15% with the standard dose.
Timeline:
The trial was conducted by pharmaceutical firm Novo Nordisk and involved over 2,000 participants. Results were published in a peer-reviewed journal last week. The study's lead author noted that while the higher dose was effective for some patients, it also increased the risk of gastrointestinal side effects such as nausea and vomiting.
Immediate Impact:
The findings have significant implications for patients who struggle with obesity and related conditions. "This study shows that a higher dose of Wegovy can be an effective option for those who don't respond well to the standard dose," said Dr. Lora Heisler, a weight loss expert at the University of Aberdeen. However, she cautioned that the increased risk of side effects must be carefully weighed against potential benefits.
Background:
Wegovy, which contains the active ingredient semaglutide, works by mimicking the action of the hormone glucagon-like peptide-1 (GLP1). This hormone helps regulate appetite and metabolism. Wegovy is approved to treat people with obesity and those who are overweight and have at least one weight-related condition like type 2 diabetes.
What Happens Next:
The study's findings will likely influence prescribing practices for Wegovy, with some doctors considering a higher dose for patients who require more aggressive treatment. However, further research is needed to fully understand the risks and benefits of this approach. As the global obesity epidemic continues to grow, innovative treatments like Wegovy are crucial in helping patients achieve sustainable weight loss.
*This story is developing. Information compiled from Newscientist reporting.*
